AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
Previous studies have suggested that immunotherapy combined with chemotherapy as neoadjuvant
treatment for ovarian cancer may have a synergistic effect and a manageable safety profile.
AK104 is a bispecific antibody targeting PD-1 and CTLA-4. Therefore, this study aimed to
evaluate the efficacy and safety of AK104 combined with chemotherapy as the neoadjuvant
treatment for advanced ovarian cancer.